GW&K Investment Management LLC boosted its stake in Abiomed Inc. (NASDAQ:ABMD) by 10.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 31,251 shares of the company’s stock after buying an additional 3,065 shares during the period. GW&K Investment Management LLC’s holdings in Abiomed were worth $3,415,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. State Street Corp boosted its stake in shares of Abiomed by 56.3% in the first quarter. State Street Corp now owns 1,316,168 shares of the company’s stock valued at $124,787,000 after buying an additional 474,209 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Abiomed by 17.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,137,738 shares of the company’s stock valued at $107,869,000 after buying an additional 167,040 shares during the last quarter. 1832 Asset Management L.P. bought a new stake in shares of Abiomed during the first quarter valued at $121,655,000. Norges Bank bought a new stake in shares of Abiomed during the fourth quarter valued at $46,385,000. Finally, Granahan Investment Management Inc. MA boosted its stake in shares of Abiomed by 11.6% in the first quarter. Granahan Investment Management Inc. MA now owns 322,383 shares of the company’s stock valued at $30,565,000 after buying an additional 33,400 shares during the last quarter. 93.65% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Abiomed Inc. (NASDAQ:ABMD) traded up 0.12% during mid-day trading on Friday, hitting $128.58. The company had a trading volume of 368,169 shares. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of 136.79 and a beta of 0.89. Abiomed Inc. has a 52-week low of $67.81 and a 52-week high of $131.16. The firm has a 50-day moving average price of $121.96 and a 200 day moving average price of $107.97.
Abiomed (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.06. The firm had revenue of $103 million for the quarter, compared to analyst estimates of $97.23 million. Abiomed had a net margin of 11.75% and a return on equity of 11.86%. Abiomed’s quarterly revenue was up 40.3% compared to the same quarter last year. During the same period last year, the company posted $0.20 EPS. Analysts expect that Abiomed Inc. will post $1.17 earnings per share for the current year.
Several equities research analysts have weighed in on the company. Leerink Swann reissued an “outperform” rating and set a $125.00 price objective on shares of Abiomed in a research note on Wednesday. Zacks Investment Research cut Abiomed from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Finally, Jefferies Group boosted their price objective on Abiomed from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Abiomed has an average rating of “Buy” and an average price target of $115.59.
In related news, Director Henri A. Termeer sold 25,866 shares of the firm’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $118.70, for a total value of $3,070,294.20. Following the transaction, the director now directly owns 325,778 shares of the company’s stock, valued at approximately $38,669,848.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Michael G. Howley sold 17,853 shares of the firm’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $119.20, for a total transaction of $2,128,077.60. Following the completion of the transaction, the vice president now directly owns 65,558 shares in the company, valued at $7,814,513.60. The disclosure for this sale can be found here. 10.00% of the stock is currently owned by corporate insiders.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abiomed Inc. (NASDAQ:ABMD).
Receive News & Ratings for Abiomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.